Skip to main content

Table 1 Patient’s demographics and clinical characteristics at baselinea as a function of azithromycin treatment response

From: Azithromycin and the microbiota of cystic fibrosis sputum

 

Relative

Responder (n = 17)

Non-Responder (n = 21)

P-value

Demographicsb

 Sex (Male:Female)

7:10

7:14

0.739

 Age (years)

26.06 (21.9–29.9)

25.2 (20.7–30.4)

0.964

 ∆F508 / ∆F508

9 (52.9)

10 (47.6)

1

 FEV1% predicted

44 (32–62)

56 (40–78)

0.270

 FVC % predicted

71 (64–87)

87 (67–99)

0.171

 Body mass index (kg/m2)

20.1 (18.8–21.4)

20.6 (18.9–22.1)

0.402

CF related diseasesb

 Pancreatic sufficiency

2 (11.7)

3 (14.2)

1

 CF-related diabetes

4 (23.5)

1 (4.7)

0.152

 CF-liver disease

4 (23.5)

2 (9.5)

0.378

 Osteopenia/Osteoporosis

5 (29.4)

10 (47.6)

0.326

Cultured pathogenb

Pseudomonas aeruginosa

13 (76.4)

15 (71.4)

1

Staphylococcus aureus

6 (35.2)

7 (33.3)

1

Haemophilus influenzae

1 (5.8)

1 (4.7)

1

Stenotrophomonas maltophilia

2 (11.7)

1 (4.7)

0.576

Escherichia coli

1 (5.8)

1 (4.7)

1

Therapiesb

 Inhaled DNase

12 (70.5)

12 (57.1)

0.506

 Inhaled colistin

0 (0)

1 (4.7)

1

 Inhaled tobramycin

6 (35.2)

7 (33.3)

1

 Inhaled hypertonic saline

5 (29.4)

9 (42.8)

0.506

 Proton pump inhibitor

4 (23.5)

9 (42.8)

0.307

 Inhaled corticosteroids

15 (88.2)

9 (42.8)

0.006

 Long-acting bronchodilator

16 (94.1)

17 (80.9)

0.355

 Short-acting bronchodilator

12 (70.5)

15 (71.4)

1

 Pancreatic enzymes

15 (88.2)

18 (85.7)

1

 Ranitidine

4 (23.5)

1 (4.7)

0.152

 CFTR-modulator

0 (0)

0 (0)

  1. Fisher exact probability test at a two-tailed or Wilcoxon rank-sum (Mann-Whitney) tests were performed
  2. CFTR Cystic fibrosis transmembrane conductance regulator
  3. aVariables were taken from the closest or same day from the Day 0 of azithromycin treatment and patients were categorized as Responder or Non-Responder based on the primary outcome definition
  4. bData are presented as n (%) or median (inter-quartile range)